MarketCap
Facebook
X
Telegram
IRadimed Corporation Financial Ratios 2025-2011 | IRMD
Brief overview of IRadimed Corporation's market valuation
This overview follows the five latest available observations from 2021 through 2025.
The current valuation set is P/E 55.76x (median 38.21x), EV/EBITDA 46.03x (median 46.03x), P/S 14.96x (median 9.2x). The current ratio basket stands about 45.9% above the five-year base, increasing sensitivity to weak reports.
Earnings yield calculated as 1/P/E is about 1.8%, showing current profit per unit of share price.
The latest available business-quality ratios are ROE 23.8%, ROA 20.7%, ROCE 27.6%. Profitability forms a strong profile, with capital and assets producing substantial returns.
PEG is 0.15x. Price is low relative to embedded growth, though the ratio depends heavily on forecast quality.
The cash conversion cycle lengthened from 169.4 days to 224.2 days, or 54.8 days. More cash is tied up in operations.
Overall picture
IRadimed Corporation demonstrates high business quality but trades at a premium to its own history. Strong future results are needed to preserve valuation.
Annual Financial Ratios IRadimed Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
55.8 | 34.8 | 30.5 | 38.2 | 61.2 | 221.9 | 30.3 | 45.5 | 307.6 | 13.4 | 28.4 | 62.4 | - | - | - |
P/S |
15.0 | 9.1 | 8.0 | 9.2 | 13.6 | 9.6 | 7.6 | 9.4 | 6.7 | 3.0 | 6.8 | 8.2 | - | - | - |
EPS |
1.8 | 1.5 | 1.4 | 1.0 | 0.8 | 0.1 | 0.8 | 0.6 | 0.1 | 0.7 | 0.7 | 0.2 | 0.3 | - | - |
EV (Enterprise Value) |
1.22 B | 629 M | 496 M | 444 M | 519 M | 263 M | 259 M | 265 M | 142 M | 84.4 M | 198 M | 121 M | -897 K | 2.33 M | - |
EBITDA per Share |
2.15 | 1.8 | 1.65 | 1.3 | 0.91 | 0.0475 | 0.877 | 0.661 | 0.244 | 1.03 | 1.07 | 0.368 | - | - | - |
EV/EBITDA |
44.5 | 27.6 | 23.8 | 27.2 | 46.0 | 435.4 | 25.1 | 36.4 | 52.3 | 7.1 | 16.6 | 36.9 | - | - | - |
PEG |
0.15 | 0.1 | 0.08 | 0.1 | 0.17 | -2.59 | 0.69 | 0.04 | -3.32 | -9.13 | 0.15 | 2.64 | - | - | - |
P/B |
13.2 | 7.7 | 7.3 | 6.7 | 7.9 | 4.9 | 5.3 | 6.8 | 4.7 | 3.0 | 6.7 | 6.1 | - | - | - |
P/CF |
50.2 | 26.1 | 39.0 | 48.8 | 50.7 | 58.6 | 29.9 | 40.3 | 59.3 | 12.3 | 29.2 | 64.7 | - | - | - |
ROE % |
23.76 | 22.15 | 24.07 | 17.41 | 12.92 | 2.23 | 17.35 | 15.03 | 1.52 | 22.62 | 23.58 | 9.81 | - | - | - |
ROA % |
20.67 | 19.56 | 18.66 | 15.00 | 11.25 | 1.93 | 14.43 | 13.01 | 1.28 | 19.40 | 21.36 | 8.80 | - | - | - |
ROCE % |
27.63 | 25.30 | 28.05 | 21.21 | 13.60 | -1.14 | 14.21 | 13.72 | 3.68 | 32.57 | 35.59 | 14.58 | - | - | - |
Current Ratio |
7.7 | 8.5 | 4.4 | 7.2 | 7.7 | 13.0 | 10.1 | 9.5 | 8.6 | 9.3 | 11.7 | 9.7 | - | - | - |
DSO |
52.7 | 56.8 | 71.0 | 63.0 | 42.4 | 52.6 | 69.1 | 50.5 | 59.8 | 42.4 | 44.6 | 45.7 | - | - | - |
DIO |
206.2 | 250.9 | 215.5 | 146.8 | 153.9 | 176.3 | 150.8 | 205.5 | 275.9 | 230.5 | 148.9 | 227.9 | - | - | - |
DPO |
34.8 | 40.5 | 43.3 | 39.2 | 26.9 | 29.5 | 41.1 | 39.1 | 43.0 | 66.5 | 62.8 | 67.5 | - | - | - |
Operating Cycle |
258.9 | 307.7 | 286.5 | 209.8 | 196.3 | 229.0 | 219.9 | 255.9 | 335.7 | 272.9 | 193.6 | 273.6 | - | - | - |
Cash Conversion Cycle |
224.2 | 267.1 | 243.2 | 170.6 | 169.4 | 199.5 | 178.7 | 216.8 | 292.7 | 206.4 | 130.7 | 206.2 | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios IRadimed Corporation
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
0.41 | 0.46 | 0.44 | 0.45 | 0.37 | - | 0.4 | 0.39 | 0.33 | - | 0.4 | 0.33 | 0.27 | - | 0.27 | 0.26 | 0.2 | - | 0.21 | 0.12 | 0.11 | - | 0.09 | -0.17 | 0.15 | - | 0.22 | 0.19 | 0.17 | - | 0.22 | 0.13 | 0.08 | - | 0.02 | 0.03 | -0.02 | - | 0.15 | 0.21 | 0.21 | - | 0.17 | 0.16 | 0.14 | - | 0.02 | 0.15 | 0.07 | - | 0.04 | 0.08 | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
0.57 | 0.6 | 0.56 | 0.54 | 0.44 | - | 0.47 | 0.46 | 0.39 | - | 0.48 | 0.41 | 0.33 | - | 0.34 | 0.34 | 0.28 | - | 0.33 | 0.16 | 0.17 | - | 0.15 | -0.19 | 0.09 | - | 0.31 | 0.27 | 0.17 | - | 0.21 | 0.24 | 0.14 | - | 0.11 | 0.09 | - | - | 0.31 | 0.32 | 0.32 | - | 0.31 | 0.26 | 0.21 | - | 0.05 | 0.24 | 0.12 | - | 0.06 | 0.12 | - | - | - | - | - | - | - | - | - |
ROE % |
22.83 | 22.90 | 23.05 | 23.53 | 22.84 | 17.64 | 24.43 | 24.44 | 23.58 | 18.15 | 23.06 | 21.18 | 19.10 | 13.81 | 17.60 | 14.95 | 12.23 | 8.26 | 10.01 | 2.77 | 3.39 | 1.19 | 5.61 | 7.62 | 14.39 | 11.51 | 17.23 | 16.04 | 14.28 | 10.96 | 11.54 | 6.90 | 2.97 | 0.96 | 5.85 | 12.27 | 18.34 | 19.05 | 24.89 | 25.54 | 23.21 | 16.05 | 17.19 | 16.22 | 13.18 | 8.52 | 13.33 | 22.48 | 2.51 | - | 4.81 | 10.30 | - | - | - | - | - | - | - | - | - |
ROA % |
19.91 | 19.98 | 20.25 | 20.84 | 20.11 | 15.51 | 21.30 | 21.08 | 20.13 | 15.43 | 19.74 | 17.38 | 15.53 | 11.03 | 12.97 | 8.67 | 10.59 | 7.15 | 8.66 | 2.41 | 2.95 | 1.03 | 4.71 | 6.33 | 12.06 | 9.57 | 14.53 | 13.65 | 12.25 | 9.49 | 9.98 | 5.94 | 2.55 | 0.81 | 5.01 | 10.51 | 15.73 | 16.33 | 21.63 | 22.46 | 20.68 | 14.54 | 15.56 | 14.63 | 11.85 | 7.63 | 11.37 | 18.34 | 2.25 | - | 3.73 | 7.99 | - | - | - | - | - | - | - | - | - |
ROCE % |
27.77 | 27.52 | 27.12 | 27.23 | 26.27 | 20.24 | 28.16 | 28.41 | 27.58 | 21.34 | 27.26 | 25.67 | 23.39 | 17.16 | 21.71 | 18.63 | 15.12 | 10.21 | 11.48 | 2.17 | 0.52 | -2.29 | 2.24 | 5.24 | 12.74 | 11.54 | 14.99 | 14.45 | 12.77 | 10.04 | 10.63 | 8.18 | 3.46 | 0.87 | 9.00 | 18.88 | 28.80 | 29.52 | 39.55 | 39.86 | 36.47 | 25.56 | 27.50 | 25.18 | 20.69 | 13.60 | 20.16 | 32.59 | 3.94 | - | 6.56 | 14.38 | - | - | - | - | - | - | - | - | - |
Current Ratio |
8.7 | 7.2 | 7.0 | 8.8 | 8.7 | 8.5 | 8.7 | 8.8 | 7.4 | 4.4 | 6.8 | 6.5 | 6.7 | 7.2 | 8.1 | - | 7.3 | 7.7 | 7.5 | 7.1 | 7.9 | 7.3 | 7.3 | 7.3 | 7.3 | 6.0 | 6.0 | 6.0 | 6.0 | 7.5 | 7.5 | 7.5 | 7.5 | 6.4 | 6.4 | 6.4 | 6.4 | 7.0 | 7.0 | 7.0 | 7.0 | 10.6 | 10.6 | 10.6 | 10.6 | 9.6 | 9.6 | 9.6 | 9.6 | 4.5 | 4.5 | 4.5 | - | - | - | - | - | - | - | - | - |
DSO |
59.3 | 56.6 | 53.3 | 52.8 | 54.4 | - | 55.6 | 63.6 | 65.5 | - | 66.0 | 64.0 | 73.1 | - | 36.2 | 23.4 | 43.2 | - | 34.0 | 39.3 | 45.2 | - | 54.2 | 61.4 | 62.4 | - | 66.8 | 72.1 | 62.2 | - | 50.5 | 52.1 | 51.3 | - | 60.6 | 62.4 | 66.8 | - | 44.9 | 34.9 | 38.9 | - | 43.0 | 46.3 | 38.0 | - | 46.9 | 38.0 | 50.6 | - | 72.9 | 32.6 | - | - | - | - | - | - | - | - | - |
DIO |
207.6 | 208.6 | 222.3 | 222.8 | 204.8 | - | 257.4 | 288.3 | 276.5 | - | 249.8 | 170.4 | 142.0 | - | 83.5 | 76.8 | 134.6 | - | 162.3 | 167.7 | 181.0 | - | 183.3 | 192.5 | 156.1 | - | 153.3 | 178.8 | 171.6 | - | 202.8 | 216.5 | 223.1 | - | 293.8 | 311.3 | 266.2 | - | 252.3 | 203.9 | 167.7 | - | 136.8 | 152.9 | 154.9 | - | 202.2 | 223.0 | 240.9 | - | 182.6 | 79.7 | - | - | - | - | - | - | - | - | - |
DPO |
34.7 | 39.9 | 41.0 | 46.0 | 43.9 | - | 27.8 | 28.0 | 34.0 | - | 66.4 | 49.8 | 43.2 | - | 15.4 | 20.1 | 29.9 | - | 27.6 | 23.7 | 26.9 | - | 30.6 | 32.2 | 34.0 | - | 41.8 | 48.8 | 39.4 | - | 38.6 | 41.2 | 38.5 | - | 45.8 | 48.5 | 58.5 | - | 72.8 | 58.8 | 56.9 | - | 57.7 | 64.5 | 56.1 | - | 59.8 | 66.0 | 73.5 | - | 58.2 | 25.4 | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | 275.6 | 275.7 | 259.2 | - | 312.9 | 351.9 | 342.0 | - | 315.8 | 234.3 | 215.1 | - | 119.8 | 100.1 | 177.7 | - | 196.4 | 207.0 | 226.2 | - | 237.6 | 254.0 | 218.5 | - | 220.1 | 251.0 | 233.8 | - | 253.2 | 268.6 | 274.4 | - | 354.4 | 373.7 | 333.0 | - | 297.2 | 238.8 | 206.6 | - | 179.8 | 199.2 | 192.9 | - | 249.1 | 261.1 | 291.5 | - | 255.6 | 112.2 | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | 234.6 | 229.7 | 215.4 | - | 285.1 | 323.9 | 307.9 | - | 249.4 | 184.5 | 171.9 | - | 104.4 | 80.0 | 147.9 | - | 168.8 | 183.3 | 199.3 | - | 206.9 | 221.8 | 184.5 | - | 178.2 | 202.2 | 194.4 | - | 214.6 | 227.4 | 235.8 | - | 308.6 | 325.2 | 274.6 | - | 224.4 | 180.0 | 149.7 | - | 122.1 | 134.7 | 136.7 | - | 189.2 | 195.1 | 218.1 | - | 197.3 | 86.8 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company IRadimed Corporation, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
France
China
Israel
Britain
Canada
